Anaplastic Large Cell Lymphoma: Molecular Pathogenesis and Treatment

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Apr 12

PMID 35406421

Authors

Xin-Rui Zhang

Pham-Ngoc Chien

Sun-Young Nam

Chan-Yeong Heo

Affiliations

Soon will be listed here.

Abstract

Anaplastic large cell lymphoma (ALCL) is an uncommon type of non-Hodgkin's lymphoma (NHL), as well as one of the subtypes of T cell lymphoma, accounting for 1 to 3% of non-Hodgkin's lymphomas and around 15% of T cell lymphomas. In 2016, the World Health Organization (WHO) classified anaplastic large cell lymphoma into four categories: ALK-positive ALCL (ALK+ALCL), ALK-negative ALCL (ALK-ALCL), primary cutaneous ALCL (pcALCL), and breast-implant-associated ALCL (BIA-ALCL), respectively. Clinical symptoms, gene changes, prognoses, and therapy differ among the four types. Large lymphoid cells with copious cytoplasm and pleomorphic characteristics with horseshoe-shaped or reniform nuclei, for example, are found in both ALK+ and ALK-ALCL. However, their epidemiology and pathogenetic origins are distinct. BIA-ALCL is currently recognized as a new provisional entity, which is a noninvasive disease with favorable results. In this review, we focus on molecular pathogenesis and management of anaplastic large cell lymphoma.

Citing Articles

Silicone breast implant-associated pathologies and T cell-mediated responses.

Jagasia P, Taritsa I, Bagdady K, Shah S, Fracol M Inflamm Res. 2025; 74(1):33.

PMID: 39891670 DOI: 10.1007/s00011-025-02006-7.

Neoadjuvant Immunotherapy and De-escalation of Surgery in Locally Advanced Breast Implant-associated Anaplastic Large Cell Lymphoma.

Salgarello M, Krupa J, Allchin R, Pilgrim S, Miall F, Di Napoli A Arch Plast Surg. 2025; 52(1):11-20.

PMID: 39845472 PMC: 11750338. DOI: 10.1055/a-2427-2066.

ALK + anaplastic large cell lymphoma involving the bladder: case report and review of the literature.

Zhao Y, Qiu W, Weng X, Gu C, Li S Diagn Pathol. 2024; 19(1):157.

PMID: 39695732 PMC: 11654092. DOI: 10.1186/s13000-024-01585-z.

Role of ALK Inhibitors in Anaplastic Large Cell Lymphoma-Experience from an Indian Center.

Indhuja M, Kesana S, Mehra N, Karunakaran P, Rajan A, Radhakrishnan V South Asian J Cancer. 2024; 13(2):121-125.

PMID: 38919655 PMC: 11196149. DOI: 10.1055/s-0042-1758353.

Malignancy-Associated Secondary Hemophagocytic Lymphohistiocytosis Mimicking an Infection: A Case Report and Review of the Literature.

Gopalakrishnan M, Ramanathan A, Jayaraman D, Shanmugam S, Scott J Cureus. 2024; 16(3):e56738.

PMID: 38650799 PMC: 11033213. DOI: 10.7759/cureus.56738.

References

Gambacorti-Passerini C, Mussolin L, Brugieres L . Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib. N Engl J Med. 2016; 374(1):95-6. DOI: 10.1056/NEJMc1511045. View

Marzec M, Zhang Q, Goradia A, Raghunath P, Liu X, Paessler M . Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A. 2008; 105(52):20852-7. PMC: 2634900. DOI: 10.1073/pnas.0810958105. View

Hruska C, Bertoli R, Young Y, Burkhart P, Googe P . Primary cutaneous anaplastic large cell lymphoma in a patient receiving adalimumab. JAAD Case Rep. 2016; 1(2):56-9. PMC: 4802551. DOI: 10.1016/j.jdcr.2014.12.006. View

Moskowitz C, Bertino J, Glassman J, Hedrick E, Hunte S, Agus D . Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol. 1999; 17(12):3776-85. DOI: 10.1200/JCO.1999.17.12.3776. View

Grulich A, Vajdic C, Cozen W . Altered immunity as a risk factor for non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. 2007; 16(3):405-8. DOI: 10.1158/1055-9965.EPI-06-1070. View

Bai R, Dieter P, Peschel C, Morris S, Duyster J . Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol Cell Biol. 1998; 18(12):6951-61. PMC: 109278. DOI: 10.1128/MCB.18.12.6951. View

Dhawale T, Shustov A . Autologous and Allogeneic Hematopoietic Cell Transplantation in Peripheral T/NK-cell Lymphomas: A Histology-Specific Review. Hematol Oncol Clin North Am. 2017; 31(2):335-357. DOI: 10.1016/j.hoc.2016.11.003. View

Oka T, Sugaya M, Cury-Martins J, Vasconcelos-Berg R, Suga H, Miyagaki T . Hematopoietic stem cell transplantation for cutaneous T-cell lymphoma: Summary of 11 cases from two facilities in Japan and Brazil. J Dermatol. 2015; 43(6):638-42. DOI: 10.1111/1346-8138.13199. View

Pulford K, Lamant L, Espinos E, Jiang Q, Xue L, Turturro F . The emerging normal and disease-related roles of anaplastic lymphoma kinase. Cell Mol Life Sci. 2004; 61(23):2939-53. DOI: 10.1007/s00018-004-4275-9. View

10.

Filippa D, Ladanyi M, WOLLNER N, Straus D, OBrien J, Portlock C . CD30 (Ki-1)-positive malignant lymphomas: clinical, immunophenotypic, histologic, and genetic characteristics and differences with Hodgkin's disease. Blood. 1996; 87(7):2905-17. View

11.

Harris N, Jaffe E, STEIN H, Banks P, Chan J, Cleary M . A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994; 84(5):1361-92. View

12.

de Bruin P, Beljaards R, van Heerde P, van der Valk P, Noorduyn L, van Krieken J . Differences in clinical behaviour and immunophenotype between primary cutaneous and primary nodal anaplastic large cell lymphoma of T-cell or null cell phenotype. Histopathology. 1993; 23(2):127-35. DOI: 10.1111/j.1365-2559.1993.tb00470.x. View

13.

Bekkenk M, Geelen F, van Voorst Vader P, Heule F, Geerts M, van Vloten W . Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000; 95(12):3653-61. View

14.

Amador C, Feldman A . How I Diagnose Anaplastic Large Cell Lymphoma. Am J Clin Pathol. 2021; 155(4):479-497. DOI: 10.1093/ajcp/aqab012. View

15.

STEIN H, Foss H, Durkop H, Marafioti T, Delsol G, Pulford K . CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000; 96(12):3681-95. View

16.

Morton L, Wang S, Devesa S, Hartge P, Weisenburger D, Linet M . Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2005; 107(1):265-76. PMC: 1895348. DOI: 10.1182/blood-2005-06-2508. View

17.

Nahar Saikia U, Sharma N, Duseja A, Bhalla A, Joshi K . Anaplastic large cell lymphoma presenting as acute liver failure: A report of two cases with review of literature. Ann Hepatol. 2010; 9(4):457-61. View

18.

Mereu E, Pellegrino E, Scarfo I, Inghirami G, Piva R . The heterogeneous landscape of ALK negative ALCL. Oncotarget. 2017; 8(11):18525-18536. PMC: 5392347. DOI: 10.18632/oncotarget.14503. View

19.

Deva A, Turner S, Kadin M, Magnusson M, Prince H, Miranda R . Etiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): Current Directions in Research. Cancers (Basel). 2020; 12(12). PMC: 7765924. DOI: 10.3390/cancers12123861. View

20.

Duyster J, Bai R, Morris S . Translocations involving anaplastic lymphoma kinase (ALK). Oncogene. 2001; 20(40):5623-37. DOI: 10.1038/sj.onc.1204594. View